key: cord-0817452-m94w0zjf
authors: Adams, Hugo J.A.; Kwee, Thomas C.; Kwee, Robert M.
title: Response
date: 2021-05-05
journal: Chest
DOI: 10.1016/j.chest.2021.01.002
sha: b9573fa66cd1f0bbfe8ab1745e69dd89c7e216ac
doc_id: 817452
cord_uid: m94w0zjf

nan

Henkel et al 2 speculated that the observation of enlarged pulmonary arteries might be related to an increase of parenchymal and predominantly intravascular pressure, due to severe COVID-19 pulmonary microangiopathy that affected the alveolar capillary network. The high incidence of microthrombosis was also thought to be suggestive of a possible underestimation of the vascular alterations associated with COVID-19 with the use of imaging, especially on unenhanced scans. 2 Henkel et al 2 concluded that both severe acute lung injury and vascular complications contribute to fatal outcomes. These considerations largely resonate with the excellent remarks by Rotzinger and Qanadli. 1 Nevertheless, the scientific evidence on the pathophysiologic condition and clinical relevance of vascular changes on chest CT imaging in COVID-19, besides frank pulmonary embolism, is still limited, and the interpretation of this limited evidence remains somewhat speculative. Further studies are warranted to understand the nature of vascular abnormalities seen on chest CT scans and how this can help to improve patient management and outcome.

Chest CT imaging signature of coronavirus disease 2019 infection: in pursuit of the scientific evidence

Lethal COVID-19: radiological-pathological correlation of the lungs

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

When Two Is Better Than One To the Editor:We compliment the retrospective study by Narain et al 1 in CHEST (March 2021) that analyzed and compared the risk of death with different immunotherapies in patients with coronavirus disease 2019 (COVID-19) . The findings of the study had some implications for the use of immunotherapy in this patient population. Specifically, the study found that the use of corticosteroids reduced the risk of death (hazard ratio [HR], 0.66; 95% CI, 0.57-0.76), but no survival advantage was observed with the use of tocilizumab, an IL-6 receptor monoclonal antibody (HR, 0.79; 95% CI,